100,848 research outputs found
A generalized method to optimize acoustic intensity field by using source array
No full textAcoustically bright zone is defined as a zone where the listener can acquire better sound quality than others. The acoustically bright zone can be generated by improving a desired acoustic variable on a selected zone, and the `zone control’ can be done by controlling multiple sources. Among many possible definitions on the acoustic variables, acoustic intensity is tried as an objective function to enhance the sound power radiation into the listening area. In previous work, acoustic intensity projected to a direction is considered as object function[J.-W. Choi and Y. –H. Kim, “Acoustic intensity optimization using source array,” in Proc. Inter-noise 2003, N777], so that one can maximize acoustic intensity component propagates to the desired direction. This approach shows that acoustic intensity field can be manipulated into a desired direction using a small number of sources, but it sometimes fails to control the direction of intensity. Extending this work, this paper presents a generalized method that can also manipulate the propagating direction of wave front. By employing normalized transfer functions between the multiple sources and measurement points during the optimization process, the directional characteristics of intensity field can be improved
Symplocarpus koreanus J. S. Lee, S. H. Kim & S. C. Kim 2021
No full textSymplocarpus koreanus J.S. Lee, S.H. Kim & S.C. Kim (2021: 2) Isotype: KOREA, Gangwon-do: Chuncheon-si, Sabuk-myeon, Goseong-ri, Mt. Yonghwasan, 21 March 2020, S. C. Kim 200321500 (NIBRVP815477; Fig. 1 -23). Paratypes: KOREA, Gyeonggi-do: Gapyeong-gun, Buk-myeon, Baekdun-ri, Mt. Yeoninsan, 3 May 2013, W. B . Lee s.n. (NIBRVP517078); Gapyeong-gun, Oeseo-myeon, Mt. Hwayasan, 26 June 2007, W. K. Paik VP-KB-377062-0173 (NIBRVP815507); Gapyeonggun, Sang-myeon, Haenghyeon-ri, Mt. Chungnyeongsan, 31 March 2012, J. H . Kim, Y. J. Kim & I. S. Yoon KIMJH12006 (3 sheets, NIBRVP355001); Gapyeong-gun, Sang-myeon, Haenghyeon-ri, Mt. Chungnyeongsan, 29 March 2016, G. H . Nam, J. H. Kim & J. K. Hong L 16001 (NIBRVP550794); Gapyeong-gun, Seorak-myeon, Mt. Yumyeongsan, 4 April 2008, B. K . Kwon 080404-375 (NIBRVP532404); Gapyeong-gun, Seorak-myeon, Mt. Yumyeongsan, 4 April 2008, G. Y . Chung ANH-en-080404- 001 (NIBRVP197125); Hanam-si, Baealmi-dong, Mt. Geomdansan, 3 April 2007, J. O . Hyun, H. K. Park & J. A. Eom VP-NAPI-377054-092 (NIBRVP111433); Namyangju-si, Hwado-eup, Mt. Cheonmasan, 15 April 2007, W. K . Paik VP-KB-377061-0133 (NIBRVP815506); Namyangju-si, Hwado-eup, Mt. Cheonmasan, 22 March 2013, Song et al. s.n. (NIBRVP464822); Namyangjusi, Onam-eup, Onam-ri, Mt. Cheonmasan, 6 April 2009, G. H . Nam, M. H. Kim & J. H. Lee VS 15 (NIBRVP206699); Namyangjusi, Onam-eup, Onam-ri, Mt. Cheonmasan, 6 April 2009, G. H . Nam, M. H. Kim & J. H. Lee VS16 (2 sheets, NIBRVP206700); Namyangju-si, Mt. Chungnyeongsan, 28 March 1999, S. P . Hong & K. W. Park 411 (NIBRVP102296). Gangwon-do: Cheorwon-gun, Geunnam-myeon, Mt. Gwangdeoksan, 12 May 1997, S. P . Hong & H. S. Choi 99 (NIBRVP102297); Donghae-si, Bugok-dong, Mita Temple, 26 April 2011, G. H . Nam & W. J. Jeong SHY2-34 (NIBRVP284290); Gangneung-si, Wangsan-myeon, Mt. Hwaranbong, 30 April 2009, J. H . Kim & H. J. Kim VP-KB-0904-0071 (NIBRVP318582); Hwacheon-gun, Mt. Baekjeoksan, 24 May 2000, K . Ch. Yang & J. D. Jung s.n. (NIBRVP102304, NIBRVP102305); Hwacheon-gun, Mt. Baekjeoksan, 3 August 2000, J. H . Kim & D. K. Kim 49 (NIBRVP102307); Hwacheon-gun, Sanae-myeon, Mt. Gwangdoeksan, 7 April 2009, G. H . Nam, M. H. Kim & J. H. Lee VS24 (2 sheets, NIBRVP206708); Hwacheon-gun, Sanae-myeon, Mt. Gwangdoeksan, 7 April 2009, G. H . Nam, M. H. Kim & J. H. Lee VS25 (2 sheets; NIBRVP206709). Chungcheongbuk-do: Danyang-gun, Gagok-myeon, Mt. Sobaecksan, 17 May 1999, C. W . Park, H. W. Lee & J. Koh 10315 (NIBRVP815505); Danyang-gun, Gagok-myeon, Mt. Sobaeksan, 20 April 2007, G. Y . Chung ANH-en-070420-013 (NIBRVP121631). Jeollabuk-do: Jangsu-gun, Gyenam-myeon, Jangan-ri, 21 September 1997, B. Y . Sun & C. H. Kim 10361 (NIBRVP815504); Jangsu-gun, Gyenam-myeon, Mt. Jangansan, 19 May 2007, B. Y . Sun 2271 (NIBRVP128343); Jangsu-gun, Gyenam-myeon, Mt. Jangansan, 19 June 2009, J. K . Ahn, S. J. Lee & Y. W. Lee CH 40006 (NIBRVP266477); Jangsu-gun, Gyenammyeon, Mt. Jangansan, 19 June 2009, J. K . Ahn, S. J. Lee & Y. W. Lee CH 40239 (NIBRVP266707); Jinan-gun, Jucheon-myeon, Daebul-ri, Mt. Unjangsan, without date, C. H . Kim & S. H. Lee 50051 (3 sheets, NIBRVP537859). Gyeongsangnam-do: Geochanggun, Buksang-myeon, Mt. Deogyusan hyangjeokbong-satgatgoljae, 31 May 2006, B. Y . Sun 1577 (4 sheets, NIBRVP119643). Note: The holotype is deposited in SKK.Published as part of Jang, Hyun-Do, Hyun, Chang-Woo, Ryu, Seah & Lee, Sang-Jun, 2022, Type specimens of vascular plants in the herbarium of the National Institute of Biological Resources (II), pp. 229-243 in Phytotaxa 539 (3) on page 237, DOI: 10.11646/phytotaxa.539.3.2, http://zenodo.org/record/636408
Author Correction: Evaluation of skin cancer resection guide using hyper‑realistic in‑vitro phantom fabricated by 3D printing
No full textThe original version of this Article contained an error in the spelling of the author Taehun Kim which was incorrectly given as Teahun Kim. The original Article has been corrected
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB
No full textRecently, resistance to additional first-line and injectable drugs was reported to be an independent risk factor for adverse outcomes in multidrug-resistant (MDR) tuberculosis (TB) patients. The aim of the present study was to confirm these observations in MDR-TB patients without Hill infection. MDR-TB patients treated at a tertiary referral hospital in South Korea between January 1996 and December 2005 were included. The unadjusted and adjusted odds ratios of adverse treatment outcome were calculated for resistance to each drug and combination of drugs using simple or multiple logistic regressions. None of the resistance to additional first-line or injectable drugs was associated with higher odds for adverse treatment outcome in 155 MDR but nonextensively drug-resistant (non-XDR) TB patients. However, streptomycin resistance was associated with 12 times the odds for adverse treatment outcome in 42 extensively drug-resistant (XDR) TB patients. Neither combinations of first-line drugs nor those of injectable drugs were associated with increased odds for adverse treatment outcomes in non-XDR MDR-TB patients or XDR-TB patients. Only streptomycin resistance among the first-line or injectable drugs was associated with adverse treatment outcomes in extensively drug-resistant tuberculosis patients without HIV infection.The present study was funded by
grant 04-2006-115-0 from the Seoul
National University College of
Medicine Research Fund (Seoul,
Republic of Korea).Kim DH, 2008, AM J RESP CRIT CARE, V178, P1075, DOI 10.1164/rccm.200801-132OCMigliori GB, 2008, EUR RESPIR J, V31, P1155, DOI 10.1183/09031936.00028708Blaas SH, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-60Yu MC, 2008, EMERG INFECT DIS, V14, P849Jeon CY, 2008, CLIN INFECT DIS, V46, P42, DOI 10.1086/524017Kim HR, 2007, CLIN INFECT DIS, V45, P1290, DOI 10.1086/522537Migliori GB, 2007, EUR RESPIR J, V30, P623, DOI 10.1183/09031936.00077307Hamilton CD, 2007, CLIN INFECT DIS, V45, P338, DOI 10.1086/519292Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1Raviglione M, 2006, INT J TUBERC LUNG D, V10, P1185Kim HJ, 2006, EUR RESPIR J, V28, P576, DOI 10.1183/09031936.06.00023006*CDCP, 2006, MMWR-MORBID MORTAL W, V55, P301*WHO, 2006, WKLY EPIDEMIOL REC, V81, P430Laserson KF, 2005, INT J TUBERC LUNG D, V9, P640Ho YII, 1997, J ANTIMICROB CHEMOTH, V40, P27HEIFETS L, 1989, ANTIMICROB AGENTS CH, V33, P1298WAYNE LG, 1974, AM REV RESPIR DIS, V109, P147
Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma
No full textPatients and methods: We collected 64 NKTCL cases and numerically quantified the amount of tumor-infiltrating FOXP3-positive Tregs by automated slide scanning and image analysis program after immunohistochemical staining using anti-FOXP3 antibody. Results: Patients were able to be classified into two end groups by their level of Tregs. Twenty-eight (44%) patients had Tregs < 50/0.40 mm(2), while 36 (56%) had Tregs >= 50/0.40 mm(2) within the tumor. The decreased number of Tregs (< 50/0.40 mm(2)) was more common in patients with poor performance status or in those presented in non-upper aerodigestive tract. However, the level of Tregs was not associated with other prognostic factors, including stage, lactate dehydrogenase level, International Prognostic Index, and NKTCL Prognostic Index. Importantly, patients with increased numbers of Tregs (>= 50/0.40 mm(2)) showed prolonged overall and progression-free survival (P = 0.0005 and P = 0.0079, respectively). The number of FOXP3-positive Tregs was an independent prognostic factor (P = 0.001) by multivariate analysis. Conclusion: Increased quantity of tumor-infiltrating Tregs predicted improved clinical outcome in NKTCL patients.Kim TM, 2008, ANN ONCOL, V19, P1477, DOI 10.1093/annonc/mdn147Baumforth KRN, 2008, AM J PATHOL, V173, P195, DOI 10.2353/ajpath.2008.070845Mittal S, 2008, BLOOD, V111, P5359, DOI 10.1182/blood-2007-08-105395Lee NR, 2008, LEUKEMIA LYMPHOMA, V49, P247, DOI 10.1080/10428190701824536CHAN JKC, 2008, WHO CLASSIFICATION T, P285Gjerdrum LM, 2007, LEUKEMIA, V21, P2512, DOI 10.1038/sj.leu.2404913Kim SJ, 2007, ANN ONCOL, V18, P1382, DOI 10.1093/annonc/mdm183Pai S, 2007, IMMUNOL CELL BIOL, V85, P370, DOI 10.1038/sj.icb.7100046Hasselblom S, 2007, BRIT J HAEMATOL, V137, P364, DOI 10.1111/j.1365-2141.2007.06593.xBossard C, 2007, BLOOD, V109, P2183, DOI 10.1180/blood-2006-07-033142Ralainirina N, 2007, J LEUKOCYTE BIOL, V81, P144, DOI 10.1189/jlb.0606409Shim SJ, 2007, INT J RADIAT ONCOL, V67, P31, DOI 10.1016/j.ijrobp.2006.07.1387Ghiringhelli F, 2006, IMMUNOL REV, V214, P229Carreras J, 2006, BLOOD, V108, P2957, DOI 10.1182/blood-2006-04-018218Lee J, 2006, J CLIN ONCOL, V24, P612, DOI 10.1200/JCO.2005.04.1384Barath S, 2006, ACTA HAEMATOL-BASEL, V116, P181, DOI 10.1159/000094678Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JC125947Kim TM, 2005, BLOOD, V106, P3785Ghiringhelli F, 2005, J EXP MED, V202, P1075, DOI 10.1084/jem.20051511Romagnani C, 2005, EUR J IMMUNOL, V35, P2452, DOI 10.1002/eji.200526069Lee J, 2005, EUR J CANCER, V41, P1402, DOI 10.1016/j.ejca.2005.03.010Alvaro T, 2005, CLIN CANCER RES, V11, P1467Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122Ichihara F, 2003, CLIN CANCER RES, V9, P4404Cheung MMC, 2002, INT J RADIAT ONCOL, V54, P182Woo EY, 2001, CANCER RES, V61, P4766Ho JWY, 1999, J CLIN PATHOL-MOL PA, V52, P269Kagami Y, 1998, BRIT J HAEMATOL, V103, P669Boulland ML, 1998, AM J PATHOL, V153, P1229Cheung MMC, 1998, J CLIN ONCOL, V16, P706Y
Functional interaction between p/CAF and human papillomavirus E2 protein
No full textp300/CREB-binding protein-associated factor (p/CAF), a transcriptional co-activator, interacts with co-activator p300/CBP and acidic transcription factors. p/CAF mediates transcriptional activation by acetylating nucleosomal histones and cellular factors. Previously we reported that CBP binds to human papillomavirus E2 and activates E2-dependent transcription (Lee, D., Lee, B., Kim, J., Kim, D. W., and Choe, J. (2000) J. Biol. Chem. 275, 7045-7051). Here we show that p/CAF binds to the human papillomavirus E2 protein in vivo and in vitro and activates E2-dependent transcription. CBP along with p/CAF synergistically activates E2-dependent transcription. In addition, the histone acetylase activity of p/CAF is required for efficient activation of E2 transcriptional activity. These results suggest that p/CAF is a transcriptional co-activator of the human papillomavirus E2 protein
Junior Recital, Terrance J. Gregory, tuba, video
No full textJunior Recital, videoJunior RecitalTerrance J. Gregory, tubaDavid Kim, pianoTuesday, December 5, 2023 at 8:00 p.m.Recital HallJames W. Black Music Center1015 Grove Avenue | Richmond, VirginiaThe presentation of this junior recital will fulfill in part the requirements for the Bachelor of Music degree in Music Education. Terrance J. Gregory studies tuba with Jeffrey Hudson
Dataset for "Aerofoil trailing-edge noise prediction models for wind turbine applications"
No full textDataset supporting:
Lau, A. S. H., Kim, J. W., Hurault, J., Vronsky, T., & Joseph, P. (2017). Aerofoil trailing-edge noise prediction models for wind turbine applications. Wind Energy.</span
Kim jesteś ateńska zamożna Pani?
No full textW: Kim jesteś człowieku? Funeralia Lednickie 13, eds. W. Dzieduszycki, J. Wrzesiński, Poznań: Stowarzyszenie Naukowe Archeologów Polskich, Oddział w Poznaniu, pp. 263-273
Measurement of the production and differential cross sections of W+W- bosons in association with jets in pp¯ collisions at ?s = 1.96TeV
No full textCitation: Aaltonen, T., Amerio, S., Amidei, D., Anastassov, A., Annovi, A., Antos, J., . . . Zucchelli, S. (2015). Measurement of the production and differential cross sections of W+W- bosons in association with jets in pp¯ collisions at ?s = 1.96TeV. Physical Review D - Particles, Fields, Gravitation and Cosmology, 91(11). doi:10.1103/PhysRevD.91.111101We present a measurement of the W-boson-pair production cross section in pp¯ collisions at 1.96 TeV center-of-mass energy and the first measurement of the differential cross section as a function of jet multiplicity and leading-jet energy. The W+W- cross section is measured in the final state comprising two charged leptons and neutrinos, where either charged lepton can be an electron or a muon. Using data collected by the CDF experiment corresponding to 9.7fb-1 of integrated luminosity, a total of 3027 collision events consistent with W+W- production are observed with an estimated background contribution of 1790 ± 190 events. The measured total cross section is ?(pp¯ ? W+W-)= 14.0 ± 0.6 (stat)-1.0+1.2 (syst) ± 0.8 (lumi) pb, consistent with the standard model prediction. © 2015; American Physical Society. All righs reserved.Additional Authors: Badgett, W.;Bae, T.;Barbaro-Galtieri, A.;Barnes, V. E.;Barnett, B. A.;Barria, P.;Bartos, P.;Bauce, M.;Bedeschi, F.;Behari, S.;Bellettini, G.;Bellinger, J.;Benjamin, D.;Beretvas, A.;Bhatti, A.;Bland, K. R.;Blumenfeld, B.;Bocci, A.;Bodek, A.;Bortoletto, D.;Boudreau, J.;Boveia, A.;Brigliadori, L.;Bromberg, C.;Brucken, E.;Budagov, J.;Budd, H. S.;Burkett, K.;Busetto, G.;Bussey, P.;Butti, P.;Buzatu, A.;Calamba, A.;Camarda, S.;Campanelli, M.;Canelli, F.;Carls, B.;Carlsmith, D.;Carosi, R.;Carrillo, S.;Casal, B.;Casarsa, M.;Castro, A.;Catastini, P.;Cauz, D.;Cavaliere, V.;Cerri, A.;Cerrito, L.;Chen, Y. C.;Chertok, M.;Chiarelli, G.;Chlachidze, G.;Cho, K.;Chokheli, D.;Clark, A.;Clarke, C.;Convery, M. E.;Conway, J.;Corbo, M.;Cordelli, M.;Cox, C. A.;Cox, D. J.;Cremonesi, M.;Cruz, D.;Cuevas, J.;Culbertson, R.;D'Ascenzo, N.;Datta, M.;De Barbaro, P.;Demortier, L.;Deninno, M.;D'Errico, M.;Devoto, F.;Di Canto, A.;Di Ruzza, B.;Dittmann, J. R.;Donati, S.;D'Onofrio, M.;Dorigo, M.;Driutti, A.;Ebina, K.;Edgar, R.;Elagin, A.;Erbacher, R.;Errede, S.;Esham, B.;Farrington, S.;Fernández Ramos, J. P.;Field, R.;Flanagan, G.;Forrest, R.;Franklin, M.;Freeman, J. C.;Frisch, H.;Funakoshi, Y.;Galloni, C.;Garfinkel, A. F.;Garosi, P.;Gerberich, H.;Gerchtein, E.;Giagu, S.;Giakoumopoulou, V.;Gibson, K.;Ginsburg, C. M.;Giokaris, N.;Giromini, P.;Glagolev, V.;Glenzinski, D.;Gold, M.;Goldin, D.;Golossanov, A.;Gomez, G.;Gomez-Ceballos, G.;Goncharov, M.;González López, O.;Gorelov, I.;Goshaw, A. T.;Goulianos, K.;Gramellini, E.;Grosso-Pilcher, C.;Group, R. C.;Guimaraes Da Costa, J.;Hahn, S. R.;Han, J. Y.;Happacher, F.;Hara, K.;Hare, M.;Harr, R. F.;Harrington-Taber, T.;Hatakeyama, K.;Hays, C.;Heinrich, J.;Herndon, M.;Hocker, A.;Hong, Z.;Hopkins, W.;Hou, S.;Hughes, R. E.;Husemann, U.;Hussein, M.;Huston, J.;Introzzi, G.;Iori, M.;Ivanov, A.;James, E.;Jang, D.;Jayatilaka, B.;Jeon, E. J.;Jindariani, S.;Jones, M.;Joo, K. K.;Jun, S. Y.;Junk, T. R.;Kambeitz, M.;Kamon, T.;Karchin, P. E.;Kasmi, A.;Kato, Y.;Ketchum, W.;Keung, J.;Kilminster, B.;Kim, D. H.;Kim, H. S.;Kim, J. E.;Kim, M. J.;Kim, S. H.;Kim, S. B.;Kim, Y. J.;Kim, Y. K.;Kimura, N.;Kirby, M.;Knoepfel, K.;Kondo, K.;Kong, D. J.;Konigsberg, J.;Kotwal, A. V.;Kreps, M.;Kroll, J.;Kruse, M.;Kuhr, T.;Kurata, M.;Laasanen, A. T.;Lammel, S.;Lancaster, M.;Lannon, K.;Latino, G.;Lee, H. S.;Lee, J. S.;Leo, S.;Leone, S.;Lewis, J. D.;Limosani, A.;Lipeles, E.;Lister, A.;Liu, H.;Liu, Q.;Liu, T.;Lockwitz, S.;Loginov, A.;Lucchesi, D.;Lucà, A.;Lueck, J.;Lujan, P.;Lukens, P.;Lungu, G.;Lys, J.;Lysak, R.;Madrak, R.;Maestro, P.;Malik, S.;Manca, G.;Manousakis-Katsikakis, A.;Marchese, L.;Margaroli, F.;Marino, P.;Matera, K.;Mattson, M. E.;Mazzacane, A.;Mazzanti, P.;McNulty, R.;Mehta, A.;Mehtala, P.;Mesropian, C.;Miao, T.;Mietlicki, D.;Mitra, A.;Miyake, H.;Moed, S.;Moggi, N.;Moon, C. S.;Moore, R.;Morello, M. J.;Mukherjee, A.;Muller, Th;Murat, P.;Mussini, M.;Nachtman, J.;Nagai, Y.;Naganoma, J.;Nakano, I.;Napier, A.;Nett, J.;Neu, C.;Nigmanov, T.;Nodulman, L.;Noh, S. Y.;Norniella, O.;Oakes, L.;Oh, S. H.;Oh, Y. D.;Oksuzian, I.;Okusawa, T.;Orava, R.;Ortolan, L.;Pagliarone, C.;Palencia, E.;Palni, P.;Papadimitriou, V.;Parker, W.;Pauletta, G.;Paulini, M.;Paus, C.;Phillips, T. J.;Piacentino, G.;Pianori, E.;Pilot, J.;Pitts, K.;Plager, C.;Pondrom, L.;Poprocki, S.;Potamianos, K.;Pranko, A.;Prokoshin, F.;Ptohos, F.;Punzi, G.;Redondo Fernández, I.;Renton, P.;Rescigno, M.;Rimondi, F.;Ristori, L.;Robson, A.;Rodriguez, T.;Rolli, S.;Ronzani, M.;Roser, R.;Rosner, J. L.;Ruffini, F.;Ruiz, A.;Russ, J.;Rusu, V.;Sakumoto, W. K.;Sakurai, Y.;Santi, L.;Sato, K.;Saveliev, V.;Savoy-Navarro, A.;Schlabach, P.;Schmidt, E. E.;Schwarz, T.;Scodellaro, L.;Scuri, F.;Seidel, S.;Seiya, Y.;Semenov, A.;Sforza, F.;Shalhout, S. Z.;Shears, T.;Shepard, P. F.;Shimojima, M.;Shochet, M.;Shreyber-Tecker, I.;Simonenko, A.;Sliwa, K.;Smith, J. R.;Snider, F. D.;Song, H.;Sorin, V.;St. Denis, R.;Stancari, M.;Stentz, D.;Strologas, J.;Sudo, Y.;Sukhanov, A.;Suslov, I.;Takemasa, K.;Takeuchi, Y.;Tang, J.;Tecchio, M.;Teng, P. K.;Thom, J.;Thomson, E.;Thukral, V.;Toback, D.;Tokar, S.;Tollefson, K.;Tomura, T.;Tonelli, D.;Torre, S.;Torretta, D.;Totaro, P.;Trovato, M.;Ukegawa, F.;Uozumi, S.;Vázquez, F.;Velev, G.;Vellidis, C.;Vernieri, C.;Vidal, M.;Vilar, R.;Vizán, J.;Vogel, M.;Volpi, G.;Wagner, P.;Wallny, R.;Wang, S. M.;Waters, D.;Wester W.C, III;Whiteson, D.;Wicklund, A. B.;Wilbur, S.;Williams, H. H.;Wilson, J. S.;Wilson, P.;Winer, B. L.;Wittich, P.;Wolbers, S.;Wolfe, H.;Wright, T.;Wu, X.;Wu, Z.;Yamamoto, K.;Yamato, D.;Yang, T.;Yang, U. K.;Yang, Y. C.;Yao, W. M.;Yeh, G. P.;Yi, K.;Yoh, J.;Yorita, K.;Yoshida, T.;Yu, G. B.;Yu, I.;Zanetti, A. M.;Zeng, Y.;Zhou, C.;Zucchelli, S
- …
